Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes

Toxicology and Applied Pharmacology

Volumn 240, Issue 3, 2009, Pages 348-354

  Rachek, Lyudmila I ^a   Yuzefovych, Larysa V ^a   LeDoux, Susan P ^a   Julie, Neil L ^b   Wilson, Glenn L ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b Shady Grove Adventist Hospital   (United States)

Author keywords

Apoptosis; Human hepatocytes; Mitochondria; Mitochondrial DNA; Rosiglitazone; Troglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; CASPASE 3; CYTOCHROME C; ENDONUCLEASE; ENDONUCLEASE III; MITOCHONDRIAL DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSACTIVATOR PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA FRAGMENTATION; HUMAN; HUMAN CELL; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER TOXICITY; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CELLS, CULTURED; CHROMANS; DNA DAMAGE; DNA, MITOCHONDRIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; THIAZOLIDINEDIONES;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349779185     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.021     Document Type: Article

References (35)

1. Bova M.P., Tam D., McMahon G., and Mattson M.N. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol. Lett. 155 (2005) 41-50
2. Chandel N.S., and Schumacker P.T. Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. FEBS Lett. 454 (1999) 173-176
3. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 41 (2005) 237-246
4. Cory A.H., Owen T.C., Barltrop J.A., and Cory J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3 (1991) 207-212
5. Crouch S.P., Kozlowski R., Slater K.J., and Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160 (1993) 81-88
6. Druzhyna N.M., Musiyenko S.I., Wilson G.L., and LeDoux S.P. Cytokines induce nitric oxide-mediated mtDNA damage and apoptosis in oligodendrocytes. Protective role of targeting 8-oxoguanine glycosylase to mitochondria. J. Biol. Chem. 280 (2005) 21673-21679
7. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., and DelloRusso C. Receptor independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 70 (2005) 177-188
8. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., and Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37 (1988) 1549-1558
9. Grishko V., Rachek L., Musiyenko S., LeDoux S.P., and Wilson G.L. Involvement of mtDNA damage in free fatty acid-induced apoptosis. Free Radic. Biol. Med. 38 (2005) 755-762
10. Haskins J.R., Rowse P., Rahbari R., and de la Iglesia F.A. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol. 75 (2001) 425-438
11. Jung J.Y., Yoo C.I., Kim H.T., Kwon C.H., Park J.Y., and Kim Y.K. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology 234 (2007) 73-82
12. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., and Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung. 47 (1997) 356-368
13. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos C., Willson T.M., and Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
14. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
15. Lim L.M., Liu J., Go M.L., and Boelsterli U.A. The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol. Sci. 101 (2008) 341-349
16. Masubuchi Y., Kano S., and Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222 (2006) 233-239
17. Narayanan P.K., Hart T., Elcock F., Zhang C., Hahn L., McFarland D., Schwartz L., Morgan D.G., and Bugelski P. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry, A 52 (2003) 28-35
18. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331 (1994) 1188-1193
19. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., and Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur. J. Pharmacol. 407 (2000) 227-235
20. Pettepher C.C., LeDoux S.P., Bohr V.A., and Wilson G.L. Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin. J. Biol. Chem. 266 (1991) 3113-3117
21. Rachek L.I., Grishko V.I., Musiyenko S.I., Kelley M.R., LeDoux S.P., and Wilson G.L. Conditional targeting of the DNA repair enzyme hOGG1 into mitochondria. J. Biol. Chem. 277 (2002) 44932-44937
22. Rachek, L.I., Grishko, V.I., Alexeyev, M.F., Pastukh, V.V., LeDoux, S.P., Wilson, G.L., 2004. Endonuclease III and endonuclease VIII conditionally targeted into mitochondria enhance mitochondrial DNA repair and cell survival following oxidative stress. 32 (10), 3240-3247.
23. Rachek L.I., Grishko V.I., LeDoux S.P., and Wilson G.L. Role of NO-induced mtDNA damage in mitochondrial dysfunction and apoptosis. Free Radic. Biol. Med. 5 (2006) 754-762
24. Rachek L.I., Thornley N.P., Grishko V.I., LeDoux S.P., and Wilson G.L. Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes 55 4 (2006) 1022-1028
25. Rachek L.I., Musiyenko S.I., LeDoux S.P., and Wilson G.L. Palmitate induced mtDNA damage and apoptosis in L6 rat skeletal muscle cells. Endocrinology 148 (2007) 293-299
26. Ruchko M., Gorodnya O., LeDoux S.P., Alexeyev M.F., Al-Mehdi A.B., and Gillespie M.N. Mitochondrial DNA damage triggers mitochondrial dysfunction and apoptosis in oxidant-challenged lung endothelial cells. Am. J. Physiol., Lung Cell. Mol. Physiol. 288 (2005) L530-535
27. Saltiel A.R., and Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45 (1996) 1661-1669
28. Santos J.H., Hunakova L., Chen Y., Bortner C., and Van Houten B. Cell sorting experiments link persistent mitochondrial DNA damage with loss of mitochondrial membrane potential and apoptotic cell death. J. Biol. Chem. 278 (2003) 1728-1734
29. Schoonjans K., Staels B., and Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302 (1996) 93-109
30. Schwarze S., Ho A., Vocero-Akbani A., and Dowdy S. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
31. Shishido S., Koga H., Harada M., Kumemura H., Hanada S., Taniguchi E., Kumashiro R., Ohira H., Sato Y., Namba M., Ueno T., and Sata M. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37 (2003) 136-147
32. Shokolenko I.N., Alexeyev M.F., LeDoux S.P., and Wilson G.L. TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair 4 (2005) 511-518
33. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16 (2003) 679-687
34. Spencer C.M., and Markham A. Troglitazone. Drugs 54 (1997) 89-101 discussion 102
35. Tirmenstein M.A., Hu C.X., Gales T.L., Maleeff B.E., Narayanan P.K., Kurali E., Hart T.K., Thomas H.C., and Schwartz L.W. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69 (2002) 131-138